Biophytis S.A. (ENXTPA: ALBPS)
Health Care · Biotechnology · FR
€0.08
-24.57% today · -55.3% 1Y
Biophytis S.A. (ENXTPA: ALBPS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.47M and employs 20 people.
Over the last twelve months the share price has lost 55.3%, trading between 0.00 and 0.21.
Tweenvest scores Biophytis S.A. across four factors: quality 5/100. Its strongest factor is quality.
ALBPS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.61
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- €0.21
- 52-week low
- €0.00
- Avg volume (3M)
- —
- Shares outstanding
- 91.62M
- Employees
- 20
- Next earnings
- —
About Biophytis S.A.
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.
- ISIN
- FR001400OLP5
- Founded
- 2006
- Listed since
- Jul 13, 2015
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | 0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.53 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.11 | +1.60% |
Figures last refreshed Aug 18, 2026.